Among others (see Table 3), a phase 1 trial (NCT01563302) revealed that systemic administration of danvartisen, an antisense oligonucleotide inhibitor of STAT3, reduced the levels of peripheral PMN-MDSCs in patients with diffuse large B-cell lymphoma (DLBCL) [211]. The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.